Dr Reddys Laboratories Stock Price To Earnings To Growth
| RDDA Stock | EUR 13.70 0.20 1.48% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDDA Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
RDDA |
Dr Reddys Laboratories Company Price To Earnings To Growth Analysis
Dr Reddys' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Dr Reddys Price To Earnings To Growth | 1.50 X |
Most of Dr Reddys' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Dr Reddys Laboratories has a Price To Earnings To Growth of 1.5031 times. This is 111.7% higher than that of the Healthcare sector and 58.22% higher than that of the Drug Manufacturers - Specialty & Generic industry. The price to earnings to growth for all Germany stocks is 69.26% higher than that of the company.
RDDA Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in price to earnings to growth category among its peers.
RDDA Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0949 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 8.47 B | |||
| Shares Outstanding | 166.1 M | |||
| Shares Owned By Institutions | 10.37 % | |||
| Price To Earning | 23.95 X | |||
| Price To Book | 3.61 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 214.39 B | |||
| Gross Profit | 113.84 B | |||
| EBITDA | 48.86 B | |||
| Net Income | 23.57 B | |||
| Cash And Equivalents | 306.55 M | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 5.75 B | |||
| Debt To Equity | 23.50 % | |||
| Current Ratio | 1.89 X | |||
| Book Value Per Share | 1,326 X | |||
| Cash Flow From Operations | 28.11 B | |||
| Earnings Per Share | 2.47 X | |||
| Price To Earnings To Growth | 1.50 X | |||
| Target Price | 77.85 | |||
| Number Of Employees | 24.8 K | |||
| Beta | 0.24 | |||
| Market Capitalization | 8.14 B | |||
| Total Asset | 296.65 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.71 % | |||
| Net Asset | 296.65 B | |||
| Last Dividend Paid | 30.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in RDDA Stock
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.